Geriatric Immunization
As we get more seasoned, our invulnerable framework has a tendency to debilitate after some time, putting us at higher hazard for specific infections. This is the reason, notwithstanding regular influenza immunization and Td or Tdap antibody, the grown-ups 60 years or more seasoned should take Pneumococcal antibodies, which secure against pneumococcal illness, incorporating diseases in the lungs and circulation system and Zoster immunization, which ensures against shingles.
Related Conference of Geriatric Immunization
March 24-25, 2026
9th International Conference on Vaccines, Immunology and Clinical Trials
Paris, France
Geriatric Immunization Conference Speakers
Recommended Sessions
- Antibiotic Resistance
- Antibiotics
- Geriatric Immunization
- HIV/AIDS Vaccines:
- Human Vaccines-Infectious & Non-Infectious:
- Immuno-oncology
- Immunology
- Maternal and Neonatal Vaccination
- Mosquito-Borne Diseases-Vaccines
- Nanotechnology in Antibiotics, Vaccines Development
- Pharmacokinetics and Pharmacodynamics of Antibiotics
- Plant Vaccination
- Side-impacts of Antibiotics and Vaccines
- Toxoid Vaccines
- Travel Immunization:
- Vaccination Advancement
- Vaccines & Immunizations
- Veterinary Vaccines
Related Journals
Are you interested in
- Advancements in Vaccine Research and Development - Vaccines R&D 2026 (France)
- Advances in Pediatric Vaccines - Vaccines R&D 2026 (France)
- Cancer Vaccines and Immunotherapy - Euro Vaccines 2025 (France)
- Childhood Vaccines and Maternal Vaccines - Euro Vaccines 2025 (France)
- Clinical Trials Design and Methodologies - Vaccines R&D 2026 (France)
- DNA Vaccines - Euro Vaccines 2025 (France)
- Emerging Infectious Diseases and Vaccine Development - Vaccines R&D 2026 (France)
- Ethical Considerations in Vaccine Development and Distribution - Vaccines R&D 2026 (France)
- Global Immunization Strategies and Policy - Vaccines R&D 2026 (France)
- Hepatitis Vaccines - Euro Vaccines 2025 (France)
- HIV/AIDS Vaccines - Euro Vaccines 2025 (France)
- Human Preventive & Therapeutic Vaccines - Euro Vaccines 2025 (France)
- Human Vaccines - Infectious & Non Infectious Diseases - Euro Vaccines 2025 (France)
- Immunology of Infectious Diseases - Vaccines R&D 2026 (France)
- Immunology/Animal Models - Euro Vaccines 2025 (France)
- Immunotherapy and Personalized Medicine - Vaccines R&D 2026 (France)
- Innovations in Vaccine Cold Chain and Storage - Vaccines R&D 2026 (France)
- Mucosal Vaccines - Euro Vaccines 2025 (France)
- Next-Generation Vaccine Delivery Technologies - Euro Vaccines 2025 (France)
- Regulatory Approaches in Vaccine Development - Vaccines R&D 2026 (France)
- Role of Adjuvants in Vaccine Efficacy - Vaccines R&D 2026 (France)
- Role of AI and Big Data in Vaccine Research - Vaccines R&D 2026 (France)
- Translational Immunology and Vaccine Development - Vaccines R&D 2026 (France)
- Vaccine Adjuvants - Euro Vaccines 2025 (France)
- Vaccine Delivery Systems: Innovations and Challenges - Vaccines R&D 2026 (France)
- Vaccine Development for Cancer Immunotherapy - Vaccines R&D 2026 (France)
- Vaccine Development for Vector-Borne Diseases - Vaccines R&D 2026 (France)
- Vaccine Equity and Access in Low-Resource Settings - Vaccines R&D 2026 (France)
- Vaccine Hesitancy and Public Perception - Vaccines R&D 2026 (France)
- Vaccine Manufacturing and Distribution - Vaccines R&D 2026 (France)
- Vaccine Research & Development - Euro Vaccines 2025 (France)
- Vaccine Safety and Pharmacovigilance - Vaccines R&D 2026 (France)
- Vaccines against Viral and Bacterial Diseases - Euro Vaccines 2025 (France)
- Vaccines Business Development - Euro Vaccines 2025 (France)
- Vaccines for Older Adults - Euro Vaccines 2025 (France)
- Vaccines for Respiratory Diseases - Euro Vaccines 2025 (France)
- Vaccines for Vector-borne Diseases - Euro Vaccines 2025 (France)
- Vaccines Safety & Efficacy - Euro Vaccines 2025 (France)
- Veterinary Vaccines - Euro Vaccines 2025 (France)